Bevacizumab trials for TNBC - Triple-Negative Breast Cancer

All Bevacizumab trials · All TNBC - Triple-Negative Breast Cancer trials

Phase breakdown

Recruiting trials studying Bevacizumab for TNBC - Triple-Negative Breast Cancer

• QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
  NCT06786026 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.
  NCT07638852 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study
  NCT06125080 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location

Common questions

How many trials study Bevacizumab for TNBC - Triple-Negative Breast Cancer?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.